AIDS and Behavior
https://doi.org/10.1007/s10461-018-02388-2
ORIGINAL PAPER
Determinants, Prevalence and Trend of Use of Medicinal Plants
Among People Living with HIV: A Cross‑Sectional Survey in Dschang,
Cameroon
Alex Mabou Tagne1 · Prosper Cabral Biapa Nya2 · Armand Tiotsia Tsapi3 · Annick Kevin Edingue Essoh4 ·
Gynette Pembouong4 · Michael Alliance Ngouadjeu Ngnintedem5 · Franca Marino1 · Marco Cosentino1
© Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract
People living with HIV (PLHIV) in Cameroon often seek care from traditional health practitioners (THPs) and use medicinal plants (MP). Most MP, however, still lacks evidence for their efficacy and safety, and their use, often undisclosed to
referring physicians, may interfere with standard therapies. Therefore, we conducted a survey of 247 PLHIV in Dschang to
assess the determinants, prevalence and trend of MP use. Besides, we surveyed 16 THPs about the use of MP in PLHIV and
HIV-related knowledge. 54.9% PLHIV declared using in total 70 plants, 91.3% users were satisfied with MP, and unwanted
effects were reported in 2 cases. MP users were less educated than nonusers, had longer disease duration and were more
often unemployed. Only 3 THPs used MP in PLHIV, and most of them had insufficient knowledge of HIV. Results may be
useful for education on HIV and integration of traditional medicines with conventional therapeutics.
Keywords Medicinal plants · Ethnobotanical survey · Prevalence · HIV/AIDS · Dschang Cameroon
Introduction
HIV/AIDS is a major public health problem, affecting circa
36.7 million people worldwide [1]. Sub-Saharan Africa,
which accounts for more than 2 in 3 people living with HIV
(PLHIV), stands out as the epicentre of this epidemic [2].
Despite efforts to combat this disease, no definitive cure or
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s10461-018-02388-2) contains
supplementary material, which is available to authorized users.
* Alex Mabou Tagne
amaboutagne@uninsubria.it
1
Centre for Research in Medical Pharmacology, University
of Insubria, Via Monte Generoso, n. 71, 21100 Varese, Italy
2
Department of Chemistry, Laboratory of Phytochemistry,
University of Dschang, Dschang, Cameroon
3
Faculty of Sciences and Technology, Evangelical University
of Cameroon, Bandjoun, Cameroon
4
Faculty of Medicine and Pharmaceutical Sciences, University
of Dschang, Dschang, Cameroon
5
School of Pharmacy, University of Camerino, Camerino,
Italy
protective vaccine has yet been discovered [3]. The advent
of combination antiretroviral therapy (cART) has made HIV/
AIDS a chronic and treatable disease [4, 5]. However, there
are still tremendous obstacles in accessing cART in some
parts of the world, especially in resource-poor settings [6].
Common barriers to cART include stigma and discrimination, poverty, shortage of health personnel, drug resistance
and the associated side effects of antiretroviral drugs [7,
8]. Overall, antiretroviral therapy still suffers from several
largely unmet medical needs, which may induce PLHIV to
seek care from complementary and/or alternative medicines
[9, 10].
Medicinal plants (MP) represent the most common source
of complementary and/or alternative medicines in different
parts of the globe, and particularly in Sub-Saharan Africa
[11]. Interest in MP lies mainly in their affordability, accessibility, cultural acceptability, perceived efficacy and safety
[12]. However, there are concerns that most MP are still
lacking supporting evidence for their efficacy, tolerability
and safety [13, 14].
MP use is widespread in Cameroon, but still, the
actual prevalence is unknown, especially among PLHIV
[15]. Indeed, current data on the prevalence of MP use
(33.7–97.3%) comes from previous research conducted
13
Vol.:(0123456789)
AIDS and Behavior
Fig. 1 Map of study area
outside Cameroon [16, 17]. Interestingly, in PLHIV under
cART, MP are often used undisclosed to referring physicians, raising concerns about possible interference with
standard therapies [13, 14]. Based on this background, we
conducted a questionnaire-based survey to determine the
prevalence, trend of use and factors associated with MP use
among PLHIV in Dschang (West Region, Cameroon).
Traditional health practitioners (THPs) are custodians of
knowledge about the traditional use of MP [18–20]. Almost
80% of the African population relies on THPs for most of
their healthcare needs, 60% of whom have sexually transmitted infections including HIV/AIDS [21–23]. Given the lack
of easily accessible conventional health facilities, the high
costs of transportation to these facilities and the shortage
of medical personnel, especially in rural and remote areas,
THPs could fill gaps in the provision of primary health care
to PLHIV. However, THPs are looked upon by many in the
conventional medical system as unfit or poorly qualified to
assist in the correct diagnosis of symptoms as well as prevention and treatment of HIV/AIDS [21]. This reluctance
to integrate traditional medicine with conventional medicine is concerning given the growing burden of the HIV
epidemic that is affecting health systems in Africa. In view
of the above, we also examined the use of MP by THPs in
PLHIV and their knowledge of HIV/AIDS with the aim to
determine if THPs are an appropriate resource to assist in the
13
scaling up of HIV prevention and treatment delivery services
in Cameroon.
Methods
Study Design and Administrative Procedure
This study was a cross-sectional questionnaire survey
carried out between January and June 2017 in the city of
Dschang. Permission to conduct this research was previously granted by the head of Dschang health district (No.
192/AR/MINSANTE/DRSPO/DSD) and the director of the
Dschang District Hospital (No. 021/AR/MSP/DRO/DSD/
HDD), respectively. Ethical approval for this study was
obtained from the Cameroon National Ethics Committee
under registration number CE No. 00172/CRERSHC/2017
(Supplementary data S1).
Study Area
Dschang is the capital city of the Ménoua division, in the
West Region of Cameroon (Fig. 1). The city of Dschang
was purposefully selected for this study because of its rich
biodiversity and long tradition of MP use [24]. Second, it
is home to about 221,031 inhabitants of different ethnic
AIDS and Behavior
and religious backgrounds. Third, the university that bears
its name (University of Dschang), whose main campus is
located in the municipality of Dschang, has largely contributed to the multi-cultural character of its population. Moreover, Dschang exhibits both the rural and urban landscapes of
Cameroon, and traditional health beliefs are widespread in
the countryside [25]. Lastly, the Dschang Health District is
divided into 22 health areas, with a total of 66 health facilities including one district hospital.
With a capacity of 300 beds, ten care units and 95 medical and paramedical staff, the Dschang District Hospital is
the reference health facility in Dschang. It has a care unit
dedicated explicitly to PLHIV, although screening, prevention and care activities are integrated into the various care
services throughout the hospital. All patients attending the
national HIV treatment program are required to report each
month to the pharmacy and at least once every 3 months to
their referring physicians, for a refill of their prescriptions,
and their medical follow-up, respectively. The psychosocial
support of PLHIV is mainly provided by trained health care
auxiliaries (psychosocial counsellors) and to some extent the
members of local HIV/AIDS associations, community relay
workers and social workers.
Participants
The survey was designed for PLHIV and THPs, and individual consent was obtained from each participant before
the beginning of the interviews. PLHIV over 18 years old
attending the national HIV treatment program were eligible
to participate in the survey. They were then enrolled consecutively between January and June 2017—without financial incentive—during routine visits to the Dschang District
Hospital (Unit care).
THPs, including healers and soothsayers, were enrolled in
this study as well. They were identified by Maurice Kenzo,
chairperson of Société Coopérative des Producteurs des
Plantes Médicinales de l’Ouest—Cameroun (Cooperative
Society of Producers of Medicinal Plants of West—Cameroon) based on their good reputation in traditional healing
practice. Respondents were members of the aforementioned
society, which has about forty members.
Interviews
Study participants were interviewed in a one-to-one fashion
and in their preferred language (English or French). Interviews of PLHIV and THPs were conducted respectively by
psychosocial counsellors and the chairperson of MP producers’ society, using a semi-structured questionnaire. In all
cases, the interview did not last more than 30 min.
The study questionnaire was designed with adaptations
according to existing literature from similar studies [26].
Then, the surveyed questions were pretested among a sample of study participants, generating changes on the initial
version of the questionnaire which was ultimately used to
collect information in the current study. At that stage of
the study, we noted reticence of PLHIV to discuss their
condition freely, as well as the reluctance of THPs to talk
with us because according to them, we were “uninitiated”
to traditional beliefs. As a corrective measure, we, therefore, chose the psychosocial counsellors and the chairperson of MP producers’ society to conduct the interviews.
The questionnaire addressed to PLHIV was a 15-item
mixed questionnaire structured into three main sections
(Supplementary data S2). The first section was dedicated
to the socio-demographic characteristics of the respondents including gender, education level, home location,
ethnicity and profession. The second part focused on the
duration since HIV diagnosis, the current cART regimen
and associated benefits/side effects. In the last section,
study participants were asked about their MP use experience for HIV symptoms management or related conditions.
Participants who acknowledged the use of MP (MP users)
were subsequently invited to provide information about
the names of plants they used, the reasons and modality of
their use as well as ratings of desired and unwanted effects.
On the other hand, the questionnaire addressed to
THPs also comprised three sections (Supplementary data
S3). The first section explored their socio-demographics.
The second section consisted of a psychometric scale to
assess their knowledge of HIV transmission, prevention
and symptoms. Further, THPs who reported to use MP
in PLHIV were interviewed about their practice activity.
The questionnaires were anonymous to ensure confidentiality, to avoid possible reticence of PLHIV to unveil
the use of MP to their healthcare givers, as well as to overcome any potential ethical or legal issues related to the use
of illegal or endangered MP by PLHIV or by THPs.
Botanical Identification of MP
MP users were invited to provide photographs or specimens of plants. If needed, field trips were made, and plants
were sampled and deposited at the University of Dschang
(Laboratory of Phytochemistry, Department of Biochemistry). At the end of the survey, a complete set of plant
specimens, together with the collection notes (plant parts,
photographs, vernacular/local name, habitat, and traditional use) were sent to the National Herbarium of Cameroon for botanical identification (Identification Number
158/IRAD/DG/CRRA-NK/SSRB-HN/07/2017).
13
AIDS and Behavior
Table 1 Demographics of HIV-infected participants and association with MP use
Features
Gender
Female
Male
Level of education
Primary
Secondary
University
Unschooled
Missing
Duration of illness in years (years since
HIV diagnosis)
≤ 2 years
3–5 years
6–9 years
> 9 years
Missing
Current cART regimen
Tenofovir/Lamivudine + Efavirenz
Tenofovir/Lamivudine + Nevirapine
Zidovudine/Lamivudine/Nevirapine
No treatment
Missing
Occupational status
Yes
No
Missing
Satisfaction with cART regimen
No
Yes
Missing
N (%)
MP nonusers (%)
MP users (%)
176 (71.3)
71 (28.7)
73 (68.9)
33 (31.1)
94 (72.9)
35 (27.1)
129 (52.2)
75 (30.4)
19 (7.7)
4 (1.6)
20 (8.1)
51 (48.1)
34 (32.1)
12 (11.3)
0 (0.0)
9 (8.5)
75 (58.1)
35 (27.1)
6 (4.7)
0 (0.0)
13 (10.1)
83 (33.6)
60 (24.3)
47 (19.0)
49 (19.8)
8 (3.2)
46 (43.4)
24 (22.6)
19 (17.9)
16 (15.1)
1 (0.9)
34 (26.4)
35 (27.1)
25 (19.4)
29 (22.5)
6 (4.7)
219 (88.7)
6 (2.4)
19 (7.7)
1 (0.4)
2 (0.8)
97 (91.5)
0 (0.0)
7 (6.6)
0 (0.0)
2 (1.887)
112 (45.3)
4 (1.6)
12 (4.9)
1 (0.4)
0 (0.0)
152 (61.5)
93 (37.7)
2 (0.8)
60 (56.6)
45 (42.5)
1 (0.9)
43 (33.3)
85 (65.9)
1 (0.8)
14 (5.7)
228 (92.3)
5 (2.0)
4 (3.8)
101 (95.3)
1 (0.9)
8 (6.2)
117 (90.7)
4 (3.1)
χ2
OR (95% CI)
P value
0.8237 (0.4679–1.450)
0.5637
4.685
0.0304
5.456
0.0019
3.952
0.1386
2.636 (1.547–4.491)
0.0004
0.5792 (0.1693–1.981)
0.5537
N sample size
Data Analysis
Data were processed in MS Excel and subsequently validated following the International Quality Standard ISO
28590:2017 guidelines. Outcome variables were presented
as counts or percentage where appropriate. The distributions
of sociodemographic and health variables among MP users
and nonusers were assessed using χ2 or Fischer’s exact tests.
The variables for which the P value was less than 5%, were
considered as determinants of MP use in PLHIV.
The psychometric scale used to assess the knowledge of
HIV/AIDS of THPs was adapted from a previously designed
questionnaire [27]. For each question, THPs were invited to
select one answer from a defined list of three choices including “true”, “false” and “don’t know”. The correct answers
were scored as “1” and the incorrect/“don’t know” responses
as “0”. The percentage of correct answers was determined
13
for each HIV knowledge item as previously reported [28].
We considered that a mean frequency of correct answers
below 50% suggests poor knowledge of HIV/AIDS. The Fischer’s exact test was used for the analysis of differences in
proportions of correct answers among THPs (MP users and
nonusers). Value of P that was under 5% was used to define
significant differences regarding knowledge of HIV/AIDS
among the two groups.
Results
Demographics of Study Participants
A total of 247 PLHIV were enrolled in this survey, and
their descriptive baseline characteristics are illustrated
in Table 1. Participants were 71.3% females, 82.6% with
AIDS and Behavior
Table 2 Reasons for
dissatisfaction with current
cART regimen of study
participants
Reported reasons for dissatisfaction with cART
n
MP users (n)
MP
nonusers
(n)
Side effects
“Decline in CD4 count”
“I stopped cART therapy a year ago because I did not perceive
any improvement in my HIV serological status”
“My work does not allow me to take my pills”
“No change in serological status”
5
2
1
2
2
1
3
0
0
1
1
1
1
0
0
n number of citations
primary or secondary education level but only 7.7%
with university degree, 1 out of three with disease duration ≤ 2 years and 1 out of five > 9 years, more than 60%
with work (although usually precarious, data not shown),
almost all on cART and 92.3% satisfied with it.
On the other hand, 16 THPs were surveyed, including
13 traditional healers and three diviners. Most of them
were males (n = 13, 81.3%) and had at least 10 years of
seniority in traditional health practice (n = 10, 62.5%).
Prevalence and Determinants of MP Use in PLHIV
235 HIV positive participants have answered the question about the use of MP (response rate = 95.1%).
Respondents reporting the use of MP but not answering open-ended questions about MP and vice versa were
considered MP users. Overall, 129 PLHIV (54.9% of the
respondents) declared having used MP to manage HIV
symptoms and related conditions. MP users were mainly
females (n = 94, 72.9% of MP users) and came from the
West region of Cameroon (n = 123, 95.3%). Most had
3–5 years of illness (n = 35, 27.1%) and primary school
education level (n = 75, 58.1%). Nearly all MP users
were currently receiving the first-line cART (n = 128,
99.2%) and most of them were satisfied with their therapy
(n = 117, 90.7%). In comparison to nonusers, MP users
were less educated (χ2 = 4.685; P < 0.05), had longer HIV
diagnosis duration (χ2 = 5.456; P < 0.01) and were more
often unemployed (Odds ratio [OR] 2.636; 95% confidence interval [CI] 1.547–4.491; P < 0.001) as presented
in Table 1. However, there was no difference between
MP users and nonusers regarding gender (OR 0.8237;
95% CI 0.4679–1.450; P = 0.6), current cART regimen
(χ2 = 3.952; P = 0.1) and satisfaction with cART regimen
(OR 0.5792; 95% CI 0.1693–1.981; P = 0.6). Dissatisfaction with cART was reported only by few subjects
(n = 8, 6.2%, 5 MP users and 3 nonusers) and the most
frequently reported reason was side effects induced by
cART as listed in Table 2.
Reasons for MP Use
MP were used with conventional drugs to manage nonHIV-related diseases (n = 94, 72.9% of MP users), to
recover from HIV-related conditions (n = 83, 64.3%), or
to cure HIV/AIDS (n = 12, 9.3%). Commonly reported
pathological conditions or symptoms treated with MP
included malaria (n = 27, 18.4% of total citations), cough
(n = 20, 13.6%) and abdominal pain (n = 16, 10.9%). The
complete list of reported diseases/symptoms treated with
MP is shown in Table 3.
The benefits of using MP reportedly ranged from moderate (n = 60, 57.7%) to complete (n = 35, 33.7%) relief,
while only eight subjects (7.7% of MP users) reported no
change in their terms. Anecdotally, two MP users claimed
Combretum micranthum G. Don was able to clear HIV.
Interestingly, of six individuals who answered the questions regarding the unwanted effects associated with MP
use, only two subjects (33.3% of respondents) denounced
fatigue and weight loss.
Table 3 Frequently reported diseases and conditions (n > 5) treated
with MP
Diseases/conditions
Occurrence (n)
% of total
reports
Malaria
Cough
Abdominal pain
Typhoid fever
Dysentery
Fever
Weakness/fatigue
Diarrhoea
Headache
Anaemia
Bile
Skin problems
Stomach hurts
27
20
16
13
11
10
10
9
9
7
5
5
5
18.4
13.6
10.9
8.8
7.5
6.8
6.8
6.1
6.1
4.8
3.4
3.4
3.4
13
AIDS and Behavior
Trend of Use of MP in PLHIV
A total of 70 MP, chiefly the herbs, were mentioned by 106
informants [82.2% of total MP users (mean ± SEM) 2.2 ± 0.2
MP/subject, min 1, max 11], of which forty-nine have been
botanically identified, and the most popular species (in at
least four users) are listed in Table 4.
MP were usually used after PLHIV started the antiretroviral treatment (n = 46, 63.0% of respondents). The plant parts
most commonly collected for the preparation of herbal remedies included the leaves (n = 129, frequency of citations:
68.3%), bark (n = 17, 9.0%) and fruits (n = 16, 8.5%). Other
ingredients such as palm oil, palm wine, and palm kernel
oil, were often added to plant-based preparations. Most frequently, MP were administered orally in the form of decoction and without any specific dosage or mode of conservation (data not shown). They were harvested and/or purchased
in the fields (n = 79, frequency of citations: 66.4%), market
(n = 26, 21.8%), traditional healers (n = 13, 10.9%) and others (n = 1, 0.8%). MP were used as self-medication (n = 63,
frequency of citations: 55.8%) or upon the recommendation
of THPs (n = 42, 37.2%), acquaintance and relatives (n = 6,
5.3%), nurse (n = 1, 0.9%) and media (n = 1, 0.9%).
Traditional Health Practitioners’ Use of MP in PLHIV
Few TPHs interviewed (n = 3, 18.8%) acknowledged the use
of MP to manage diseases in PLHIV. Specifically, the leaves
of Aloe vera (n = 3), Moringa oleifera (n = 1) and “Mbeuheu
Ser”1 (n = 1), were administered orally in the form of infusion or decoction with the purpose to treat symptomatic
conditions such as diarrhoea (n = 1). Other desired goals
include strengthening immune function (n = 1) and increasing CD4 + T cell count (n = 1). Beyond the bitter taste of MP
extracts, HIV-infected clients claimed no unwanted effects.
Traditional Health Practitioners’ Knowledge of HIV/
AIDS
All THPs who agreed to participate in the survey were also
evaluated for their knowledge of HIV transmission, prevention and diagnosis. Regarding HIV transmission, all
respondents knew that a pregnant woman with HIV can
give the virus to her unborn baby and a person can get HIV
even if she or he has sex with another person only one time.
Ten THPs were aware that it is possible to get HIV when a
person gets a tattoo (n = 10), while a greater number believed
that showering, or washing one’s genitals/private parts after
sex keeps a person from getting HIV (n = 13). Interestingly,
some THPs believed that HIV can be spread by mosquitoes
1
Name of the plant in a local language (Yemba, Dschang).
13
(n = 4) and that a person can get HIV from a toilet seat as
well as through contact with saliva, tears, sweat, or urine
(n = 7). The majority ignored that coughing and sneezing
do not spread HIV (n = 11), while all believed that pulling
out the penis before a man climaxes keeps a woman from
getting HIV during sex.
Concerning HIV prevention, all THPs were aware that
having sex with more than one partner can increase a person’s chance of being infected with HIV. The majority knew
that there is a female condom that can help decrease a woman’s chance of getting HIV (n = 14). However, almost all
THPs interviewed believed that there is a vaccine that can
stop adults from getting HIV (n = 15).
Regarding HIV diagnosis, all THPs believed that HIV and
AIDS are the same and there is a cure for AIDS. Only a few
THPs knew that a person with HIV can look and feel healthy
(n = 7) and that taking a test for HIV 1 week after having sex
will tell a person if she or he has HIV (n = 5).
The HIV-related knowledge of THPs was assessed as
the percentage of correct responses as presented in Table 5.
Overall, the mean frequency of correct answers was relatively low (48.0% of correct answers). Interestingly, THPs
who reported the use of MP in PLHIV provided a higher
proportion of correct answers in comparison to nonusers,
although the difference between the two proportions was
not statistically significant (58.3% of correct answers vs
45.7% for the nonusers; OR 1.665; 95% CI 0.8820–3.144;
P = 0.149).
Discussion
MP use is popular in Cameroon; however, the current use
prevalence among various categories of patients remains
undetermined. The present study sought to gain a crosssectional picture of the overall use of MP in the HIV-infected
population. We observed that 54.9% of PLHIV in Dschang
used MP. This finding is not so surprising as it reflects the
status of the use of MP, estimated to nearly 80% in the general population in Cameroon [15, 29]. However, our prevalence estimate is marginally higher than the 33.7% use prevalence in Uganda and lower than the 97.3% use prevalence
among PLHIV in Trinidad [16, 17]. This discrepancy could
stem from the diverse sociodemographic and sociocultural
features of the informants as well as the difference in their
access to conventional cares, and the heterogeneity in the
design of the different surveys.
Typical MP users were less educated than nonusers, unlike previous research [9, 16, 30–33]. This can be
explained by the fact that less educated PLHIV are more
likely to be influenced in their decision to use MP compared to their more educated counterparts. This assumption is supported by our finding that the decision to use MP
Users (n) Scientific
names
Vernacular/common
names
Part used Reasons for use
20
Fipagrassi; Fhou
Ngouoya/Citronelle
L
Goyavier
B; L; R
x
Papayer
F; L; R
x
Tchouamo’o/roi des
herbes
L
x
Manguier
B; L; R
x
Citron
F
x
Aloe
L
x
Ananas
F
Pkwem/Cassava
L
Ecalyptus
L
Massep; basilic sauvage; Kotmajo
L
Pia’a/avocat
L
16
15
12
12
11
9
7
7
6
6
5
4
13
Cymbopogon
citratus
(DC.) Stapf
Psidium guajava L.
Carica
papaya L.
Ageratum
conyzoides
(L.) L.
Mangifera
indica L.
Citrus limon
(L.) Osbeck
Aloe barbadensis
Mill.
Ananas
comosus
(L.) Merr.
Manihot
esculenta
Crantz
Eucalyptus
globulus
Labill.
Ocimum
gratissimum L.
Persea
americana
Mill.
Eremomastax
speciosa
(Hochst.)
Cufod.
Fever Stomach
Abdom- Anaemia Bile Cold Cough Diarhurts
rhoea/
inal
dysentery
pain
Houeou;Wouomekwa; L
Panzem ze mo’/
rouge un côté
x
x
x
x
x
x
x
x
x
x
x
x
xc
x
x
x
xd
x
x
x
x
x
x
x
x
x
x
xe
x
x
x
xf
x
x
x
x
x
x
x
x
x
x
x
xb
x
xg
x
x
x
x
x
x
x
xa
x
x
x
Weakness Other
x
x
x
Headache Malaria Typhoid
fever
x
xh
AIDS and Behavior
Table 4 Most popular (in at least 4 users) MP listed
13
Table 4 (continued)
Users (n) Scientific
names
4
4
4
Vernacular/common
names
Part used Reasons for use
Djoudjou; Ntonkenou’ L
Kalanchoe
crenata
(Andrews)
Haw.
bitter leaf/Ndolè
L
Vernonia
amygdalina
Delile
Unidentified Tseutseuneck/épingle
noir
Fever Stomach
Abdom- Anaemia Bile Cold Cough Diarhurts
rhoea/
inal
dysentery
pain
x
x
Headache Malaria Typhoid
fever
Weakness Other
xi
x
x
x
x
x
x
x
B bark, F fruits, L leaves, R roots
a
Oedema, hypertension, itching, diabetes
b
Indigestion
c
“poison de nuit”: it refers to the afflictions suffered after a meal ingested during a dream
d
Chest pain, nightmare
e
Tuberculosis
f
Foot cramps
g
Nausea, constipation
h
Nappy rash
i
Otitis
AIDS and Behavior
AIDS and Behavior
Table 5 Frequency of correct answers for each HIV-related knowledge item
HIV knowledge item
N (%)
Users (%)
Nonusers (%)
A pregnant woman with HIV can give the virus to her unborn baby (T)
A person can get HIV even if she or he has sex with another person only one time (T)
Having sex with more than one partner can increase a person’s chance of being infected with HIV (T)
There is a female condom that can help decrease a woman’s chance of getting HIV (T)
HIV can be spread by mosquitoes (F)
It is possible to get HIV when a person gets a tattoo (T)
A person can get HIV from a toilet seat (F)
A person can get HIV through contact with saliva, tears, sweat, or urine (F)
A person with HIV can look and feel healthy (T)
Coughing and sneezing DO NOT spread HIV (T)
Taking a test for HIV 1 week after having sex will tell a person if she or he has HIV (T)
Showering, or washing one’s genitals/private parts, after sex keeps a person from getting HIV (F)
There is a vaccine that can stop adults from getting HIV (F)
HIV and AIDS are the same thing (F)
There is a cure for AIDS (F)
Pulling out the penis before a man climaxes/cums keeps a woman from getting HIV during sex (F)
Total
16 (100)
16 (100)
16 (100)
14 (87.5)
12 (75.0)
10 (62.5)
9 (56.3)
9 (56.3)
7 (43.8)
5 (31.3)
5 (31.3)
3 (18.8)
1 (6.3)
0 (0.0)
0 (0.0)
0 (0.0)
123 (48.0)
3 (100)
3 (100)
3 (100)
3 (100)
3 (100)
3 (100)
3 (100)
2 (66.7)
2 (66.7)
0 (0.0)
3 (100)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
28 (58.3)
13 (100)
13 (100)
13 (100)
11 (84.6)
9 (69.2)
7 (53.8)
6 (46.2)
7 (53.8)
5 (38.5)
5 (38.5)
2 (15.4)
3 (23.1)
1 (7.7)
0 (0.0)
0 (0.0)
0 (0.0)
95 (45.7)
Correct answers appear in parentheses (T true, F false)
was usually influenced by the recommendation of THPs,
acquaintance and relatives, nurse or the mass media. In addition, less educated MP users are likely to be low-income
earners. Consequently, their access to conventional health
care is financially limited and, as such, they may likely look
for inexpensive treatment options such as MP, to meet their
health care needs. This speculation seems to be corroborated by our finding that MP users were more likely to be
unemployed, although such observation, was not in keeping
with previous research in which MP use was associated with
more significant financial resources [31, 34]. In line with
prior studies [9, 33, 35], we found that PLHIV with longer
disease duration were more inclined to use MP than nonusers. One possible explanation could be that the long-term
toxicity of cART, as well as its lack of effectiveness over
time, may lead PLHIV to seek alternative or complementary
medicines such as MP.
Use of MP is considered a proxy for some unmet needs
of conventional therapies [26]. In the current study, however, almost all MP users were satisfied with their cART
regimen. Notwithstanding, they used MP, not instead
of standard therapies, but rather as an adjunct to manage diseases/conditions they face. This finding, somewhat surprising, should be perceived in a positive tone
since MP use did not compromise adherence to antiretroviral therapy, which is a pressing concern among MP
users [36, 37]. Our result can be explained by the fact that
there are misconceptions that attribute the cause of HIV/
AIDS to supernatural forces or witchcraft [38]. This may
prone PLHIV under cART to seek help from traditional
medicine whose therapeutic approach is primarily based
on MP. This speculation can be supported by our finding that THPs were the main advisors of the use of MP.
Moreover, MP were more often self-prescribed, suggesting
they are an integral part of the daily life of PLHIV who
wish, through their use, to align with their cultural and
spiritual behaviours and beliefs.
However, the concurrent use of MP and cART or other
allopathic medicines is concerning given the possibility of
herb-drug interferences which may jeopardise the efficacy
and tolerability of conventional therapies [39, 40]. Also, the
risk of adverse drug reactions increases with the fact that
MP were mainly used without appropriate medical supervision. The lack of medical monitoring is attributable to the
fact that physicians are not adequately educated on MP and
are reluctant to MP use [41]. Additionally, MP use is not
frequently asked during the consultation and, if otherwise,
patients most often ignore the name of the used plants [42,
43]. Putting together, these findings strengthen the need for
physicians to routinely enquire their HIV-infected patients
about the potential use of MP during the consultation. This
will create a platform to discuss the risk and benefits of MP
use by their patients and provide appropriate educational
intervention. Alternatively, the patients’ descriptive characteristics such as the occupational status, educational level
and disease duration, may be applied by the physician in
detecting the most likely MP users and, therefore, in addressing relevant and personalised educational interventions. The
effectiveness of such a discussion requires physicians to be
knowledgeable about the commonly used MP in PLHIV.
13
AIDS and Behavior
MP were mainly used to improve the lifestyle of PLHIV;
only a few of them used MP to clear the virus. Most informants claimed benefits from the use of MP. Importantly,
anecdotal reports suggest that the leaves of Kinkéliba 2
(Combretum micranthum G.Don, Combretaceae) were able
to eradicate HIV. The question of whether these claims on
benefits retrieved from MP use correspond to a real clinical
benefit still awaits further research. So far, however, among
the cited MP, at least the leaves of Aloe species and Persea
americana Mill. have supporting scientific evidence for their
anti-HIV1 activity [44, 45]. Interestingly, unpleasant side
effects related to MP were reportedly mild and denounced
only in few cases. Some caution is however required in interpreting this finding since MP users are less likely to report
side effects [46]. Indeed, in the current survey, we observed
that only 6 out of 129 MP users answered the question about
side effects associated with MP. The underlying explanation
may lie in patients’ perception of MP as “natural” and therefore effective or at least risk-free [42, 43, 47]. All in all, these
findings suggest that PLHIV perceives MP as a safer and
more effective adjunct to improving their health concerns.
MP were usually harvested in the wild and such an easy
access modality to MP may also account for their high use
prevalence in PLHIV. Leaves were the MP part most frequently used, which is less detrimental to the plant species.
Only 1 out of 70 reported MP (Garcinia kola Heckel) is
listed so far as endangered species in Cameroon [48]. The
most commonly mentioned MP including Aloe barbadensis Mill., Ageratum conyzoides (L.) L., Mangifera indica
L., Cymbopogon citratus (DC.) Stapf, Eucalyptus globulus
Labill., Ocimum gratissimum L., Carica papaya L., Vernonia amygdalina Delile, Persea americana Mill., and Psidium
guajava L., have also been reported in similar surveys conducted in Uganda [49, 50], Gabon [51], South Africa [52]
and Nigeria [53], indicating convergent local ethnomedical
traditions, possibly suggesting a sharing of ethnobotanical
knowledge between these countries due to their geographical
proximity and the migratory processes.
THPs were the main advisors of PLHIV on the use of
MP, suggesting they hold in high esteem in the HIV-infected
community. Thus, in the rest of our study, their knowledge
and attitudes towards HIV/AIDS were surveyed aiming at
understanding whether they may be an appropriate resource
to assist in the scaling up of HIV prevention and treatment
delivery services in Cameroon. We found that 3 out of the
16 THPs surveyed used MP in PLHIV, indicating that THPs
are already involved in the local delivery of health services
to PLHIV. Amongst the cited MP, Moringa oleifera Lam.
and Aloe vera (L.) Burm.f. have also been reported elsewhere in similar studies [54–57]. Though PLHIV widely
2
Common/local name of the plant species.
13
values these plants, there is some evidence to suggest they
may compromise the efficacy of antiretroviral drugs [44, 58,
59]. However, the concern raised by conventional healthcare
providers about the THPs’ inability to effectively assist them
in HIV national program is understandable given that THPs
surveyed globally had relatively low levels of HIV-related
knowledge. Nevertheless, given the shortage of health staff
and the burden of HIV/AIDS in this part of the globe, THPs
need to be educated on HIV/AIDS, as part of a program aiming to integrate traditional medicine in a global response to
HIV/AIDS epidemic.
Study Limitations and Strengths
PLHIV were enrolled from attendees of the national HIV
treatment program, who generally receive cART and other
conventional cares [60], missing, however, the experiences
of patients who were not engaged in that program. The clinical profile and attitudes towards MP of those patients may be
very different from the interviewed respondents. Therefore,
the reported prevalence of MP use among PLHIV might
be an underestimation of the real use prevalence as there is
potential selection bias in study participation. On the other
hand, our results did not represent the views of THPs nonmembers of MP producers’ association, which may differ
from those of people belonging to that organisation. Lastly,
this study was conducted in Dschang, and as such, did not
represent the views of the entire population of PLHIV and
THPs in Cameroon. Follow-up studies conducted nationwide
or in other localities are needed to assess the consistency of
our findings. This study presents the first empirical evidence
in Cameroon of the use of MP in PLHIV and evaluates the
knowledge of THPs on HIV/AIDS. Therefore, it may lay the
groundwork for designing proper data collection instruments
for a more extensive scale survey.
This kind of research usually is exposed to recall bias.
The face-to-face interview was purposefully used as previously recommended to improve informants’ recall and assist
them in their answers [61]. In this specific regard, as far as
we are concerned, patients’ interviews were conducted in
a private room by a psychosocial counsellor to avoid their
reticence to disclose the use of MP to their caring physicians and to discuss their condition freely. On the other hand,
THPs’ interviews were run by the chairperson of MP producers’ association to avoid them being reluctant to discuss
with people inexperienced in traditional beliefs.
In this study, we relied solely on self-reported MP use to
categorise study participants into users and nonusers, and
this approach can sometimes be inaccurate. In prospect, it
would be worth considering the possibility to assess the
plasma concentrations of the reported MP or their metabolites in all study participants, as well as to collect data from
AIDS and Behavior
the hospital records of PLHIV, to assess their clinical conditions objectively. The lack of statistically significant differences between MP users and nonusers among THPs may be
due to the small sample size. Therefore, future research is
required in a larger sample.
Conclusions
PLHIV, though satisfied with their cART regimen, frequently use MP to improve their conditions. However, MP
are used concomitantly with conventional medicines, raising
the risk of severe side effects. Given the possibility that MP
may also jeopardise the efficacy and tolerability of standard
therapies, physicians need to be educated on the use of MP.
Likewise, they should systematically assess the use of MP
in their patients during routine visits to provide them with
appropriate advice. Traditional knowledge of MP should
be examined on purpose to make the most of the use of
plants. THPs occupy an outstanding position in the HIVinfected community and can, therefore, assist conventional
health care providers in the scaling up of HIV prevention
and treatment delivery services in Cameroon. Importantly,
some of THPs use MP in PLHIV, although their knowledge
of the disease is relatively low. Therefore, they need to be
educated on HIV/AIDS, as part of a program aiming to integrate traditional medicine in a global response to the HIV/
AIDS epidemic.
Acknowledgements We would like to express our gratefulness to all
study participants for their cooperation, clinical staff for their support,
and local authorities for permission to conduct our research. In addition, the authors would like to acknowledge the contribution of Maurice
Kenzo, chairperson of SOCOPMO, who run the interviews with traditional practitioners. AMT holds a PhD fellowship and is enrolled in
the PhD program in Clinical and Experimental Medicine and Medical
Humanities at the University of Insubria in Varese (I).
Author Contributions Conception and design of the survey: FM MC
AMT PCBN ATT GP. Data collection: ATT PCBNAKEE GP MANN.
Data analysis: MC AMT FM. Interpretation of results: MC FM AMT
ATT MANN.Drafting of the manuscript: MC AMT FM. All authors
were involved in revising it critically forimportant intellectual content,
and all authors approved the final version to be published. All authorsagree to be accountable for all aspects of the work in ensuring that
questions related to the accuracy orintegrity of any part of the work are
appropriately investigated and resolved and declare to haveconfidence
in the integrity of the contributions of their co-authors.
Compliance with Ethical Standards
Conflict of interest All authors declare that they have no conflict of
interest.
Ethical Approval All procedures performed in studies involving human
participants were in accordancewith the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed Consent Informed consent was obtained from all individual
participants included in the study.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Latest
statistics on the status of the AIDS epidemic. Fact Sheets. 2018.
http://www.unaids.org/en/resources/fact-sheet. Accessed 13 June
2018.
2. Kharsany ABM, Karim QA. HIV infection and AIDS in SubSaharan Africa: current status, challenges and opportunities. Open
AIDS J. 2016;10(1):34–48.
3. Haynes BF, Burton DR. Developing an HIV vaccine. Science.
2017;355(6330):1129–30.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos
P, et al. Changing patterns of mortality across Europe in patients
infected with HIV-1. Lancet. 1998;352(9142):1725–30.
5. Zhou J, Sirisanthana T, Kiertiburanakul S, Chen Y-MA, Han N,
Lim P, et al. Trends in CD4 counts in HIV-infected patients with
HIV viral load monitoring while on combination antiretroviral
treatment: results from The TREAT Asia HIV Observational
Database. BMC Infect Dis. 2010;10(1):361.
6. Posse M, Meheus F, Van Asten H, Van Der Ven A, Baltussen R.
Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health. 2008;13(7):904–13.
7. Swami A. Metabolic syndrome and HIV infection. J HIV Retro
Virus. 2016;2(1):9.
8. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther.
2006;13(3):248–60.
9. Colebunders R, Dreezen C, Florence E, Pelgrom Y, Schrooten W,
Eurosupport Study Group. The use of complementary and alternative medicine by persons with HIV infection in Europe. Int J STD
AIDS. 2003;14(10):672–4.
10. Astin JA. Why patients use alternative medicine. JAMA.
1998;279(19):1548.
11. Suwankhong D, Liamputtong P, Runbold B. Traditional healers
(mor pheun baan) in Southern Thailand: the barriers for cooperation with modern health care delivery. J Community Health.
2011;36(3):431–7.
12. Green EC. The participation of African traditional healers in
AIDS/STD prevention programmes. London: Trop Doct.; 1997.
13. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21(5):404–28.
14. Moreira DL, Teixeira SS, Monteiro MHD, De-Oliveira ACAX,
Paumgartten FJR. Traditional use and safety of herbal medicines.
Rev Bras Farmacogn. 2014;24(2):248–57.
15. Kuete V, Efferth T. Cameroonian medicinal plants: pharmacology
and derived natural products. Front Pharmacol. 2010;1:123.
16. Bahall M. Prevalence, patterns, and perceived value of complementary and alternative medicine among HIV patients: a descriptive study. BMC Complement Altern Med. 2017;17(1):422.
17. Namuddu B, Kalyango JN, Karamagi C, Mudiope P, Sumba S,
Kalende H, et al. Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. BMC Public Health. 2011;11(1):855.
18. Mathibela MK, Egan BA, Du Plessis HJ, Potgieter MJ. Sociocultural profile of Bapedi traditional healers as indigenous
knowledge custodians and conservation partners in the Blouberg
area, Limpopo Province, South Africa. J Ethnobiol Ethnomed.
2015;11(1):49.
19. Petrovska BB. Historical review of medicinal plants’ usage. Pharmacogn Rev. 2012;6(11):1–5.
13
AIDS and Behavior
20. Peltzer K, Mngqundaniso N. Patients consulting traditional
health practitioners in the context of HIV/AIDS in urban areas
in KwaZulu-Natal, South Africa. Afr J Tradit Complement
Altern Med. 2008;5(4):370–9.
21. Kaboru BB, Falkenberg T, Ndubani P, Höjer B, Vongo R,
Brugha R, et al. Can biomedical and traditional health care
providers work together? Zambian practitioners’ experiences
and attitudes towards collaboration in relation to STIs and
HIV/AIDS care: a cross-sectional study. Hum Resour Health.
2006;4(1):16.
22. Green EC, Zokwe B, Dupree JD. The experience of an AIDS
prevention program focused on South African traditional healers.
Soc Sci Med. 1995;40(4):503–15.
23. Mahomoodally MF. Traditional medicines in Africa: an appraisal
of ten potent African medicinal plants. Evid Based Complement
Alternat Med. 2013;2013:617459.
24. Yemele MD, Telefo PB, Lienou LL, Tagne SR, Fodouop CSP,
Goka CS, et al. Ethnobotanical survey of medicinal plants used
for pregnant women׳s health conditions in Menoua division-West
Cameroon. J Ethnopharmacol. 2015;160:14–31.
25. Chance EA. The practices of the traditional caring culture and
western nursing culture in Cameroon. Master’s thesis. The University of Bergen, 2015.
26. Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, et al. Use of herbal remedies by multiple sclerosis patients:
a nation-wide survey in Italy. Neurol Sci. 2016;37(4):613–22.
27. Carey MP, Schroder KEE. Development and psychometric evaluation of the brief HIV Knowledge Questionnaire. AIDS Educ Prev.
2002;14(2):172–82.
28. Saddki N, Sulaiman Z, Abdullah S, Zakaria N, Mohamad N,
Ab Razak A, et al. HIV-related knowledge among people living
with HIV/AIDS in Kelantan, Malaysia. J HIV AIDS Soc Serv.
2016;15(2):216–33.
29. Fokunang CN, Ndikum V, Tabi OY, Jiofack RB, Ngameni B,
Guedje NM, et al. Traditional medicine: past, present and future
research and development prospects and integration in the
National Health System of Cameroon. Afr J Tradit Complement
Altern Med. 2011;8(3):284–95.
30. Bates BR, Kissinger P, Bessinger RE. Complementary therapy
use among HIV-infected patients. AIDS Patient Care STDS.
1996;10(1):32–6.
31. Bica I, Tang AM, Skinner S, Spiegelman D, Knox T, Gorbach
S, et al. Use of complementary and alternative therapies by
patients with human immunodeficiency virus disease in the era
of highly active antiretroviral therapy. J Altern Complement Med.
2003;9(1):65–76.
32. Hsiao A-F, Wong MD, Kanouse DE, Collins RL, Liu H, Andersen
RM, et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J
Acquir Immune Defic Syndr. 2003;33(2):157–65.
33. Mikhail IS, DiClemente R, Person S, Davies S, Elliott E, Wingood
G, et al. Association of complementary and alternative medicines
with HIV clinical disease among a cohort of women living with
HIV/AIDS. J Acquir Immune Defic Syndr. 2004;37(3):1415–22.
34. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J.
Use of complementary and alternative therapies in HIV-infected
patients. AIDS Patient Care STDS. 2001;15(3):159–67.
35. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29(4):358–67.
36. Owen-Smith A, Diclemente R, Wingood G. Complementary and
alternative medicine use decreases adherence to HAART in HIVpositive women. AIDS Care. 2007;19(5):589–93.
37. Jernewall N, Zea MC, Reisen CA, Poppen PJ. Complementary and
alternative medicine and adherence to care among HIV-positive
Latino gay and bisexual men. AIDS Care. 2005;17(5):601–9.
13
38. Bogart LM, Skinner D, Weinhardt LS, Glasman L, Sitzler C,
Toefy Y, et al. HIV misconceptions associated with condom use
among black South Africans: an exploratory study. Afr J AIDS
Res. 2011;10(2):181–7.
39. Fu g h - B e r m a n A. H e r b - d r u g i n t e ra c t i o n s . L a n c et .
2000;355(9198):134–8.
40. Lee LS, Andrade ASA, Flexner C. HIV/AIDS: interactions
between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis.
2006;43(8):1052–9.
41. Milden SP, Stokols D. Physicians’ attitudes and practices regarding complementary and alternative medicine. Behav Med.
2004;30(2):73–84.
42. Levine MAH, Xu S, Gaebel K, Brazier N, Bédard M, Brazil K,
et al. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians. Am J Geriatr Pharmacother. 2009;7(6):383–92.
43. Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, Wallace RB.
Use of herbs among adults based on evidence-based indications:
findings from the National Health Interview Survey. Mayo Clin
Proc. 2007;82(5):561–6.
44. Olatunya OS, Olatunya AM, Anyabolu HC, Adejuyigbe EA,
Oyelami OA. Preliminary trial of aloe vera gruel on HIV infection. J Altern Complement Med. 2012;18(9):850–3.
45. Wigg MD, Ai-Jabri AA, Costa SS, Race E, Bod B, Oxford JS. Invitro virucidal and virustatic anti HIV-1 effects of extracts from
Persea americana Mill. (avocado) leaves. Antivir Chem Chemother. 1996;7(4):179–83.
46. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States,
2002. Adv Data. 2004;343:1–19.
47. Gardiner P, Graham R, Legedza ATR, Ahn AC, Eisenberg DM,
Phillips RS. Factors associated with herbal therapy use by adults
in the United States. Altern Ther Health Med. 2007;13(2):22–9.
48. Glenn CR. Earth’s endangered creatures—Garcinia spp.
Facts. In: Wikipedia. 2006. http://earth senda ngere d.com/profi
le.asp?gr=P&sp=17482. Accessed 13 June 2018.
49. Nyamukuru A, Tabuti JR, Lamorde M, Kato B, Sekagya Y,
Aduma PR. Medicinal plants and traditional treatment practices
used in the management of HIV/AIDS clients in Mpigi District,
Uganda. J Herb Med. 2017;7:51–8.
50. Mugisha MK, Asiimwe S, Namutebi A, Borg-Karlson A-K, Kakudidi EK. Ethnobotanical study of indigenous knowledge on medicinal and nutritious plants used to manage opportunistic infections
associated with HIV/AIDS in western Uganda. J Ethnopharmacol.
2014;155(1):194–202.
51. Feuya Tchouya GR, Souza A, Tchouankeu JC, Yala J-F, Boukandou M, Foundikou H, et al. Ethnopharmacological surveys and
pharmacological studies of plants used in traditional medicine in
the treatment of HIV/AIDS opportunistic diseases in Gabon. J
Ethnopharmacol. 2015;13(162):306–16.
52. Babb DA, Pemba L, Seatlanyane P, Charalambous S, Churchyard
GJ, Grant AD. Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol
Health Med. 2007;12(3):314–20.
53. Igoli JO, Ogaji OG, Tor-Anyiin TA, Igoli NP. Traditional medicine practice amongst the IGEDE People of Nigeria, Part II. Afr
J Tradit Complement Altern Med. 2005;2(2):134–52.
54. Tshingani K, Donnen P, Mukumbi H, Duez P, Dramaix-Wilmet
M. Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and
immune response of HIV patients on antiretroviral therapy: a
single-blind randomized control trial. BMC Complement Altern
Med. 2017;17(1):420.
55. Mbereko A, Mahlatini P. Understanding contributions of traditional healers to the prevention, care and support in the fight
AIDS and Behavior
56.
57.
58.
59.
against HIV and AIDS Pandemic in Kariba, Zimbabwe. Int J
Sociol Anthropol. 2014;6(4):136–45.
Monera TG, Maponga CC. Prevalence and patterns of Moringa
oleifera use among HIV positive patients in Zimbabwe: a crosssectional survey. J Public Health Africa. 2012;3(1):6.
Popoola JO, Obembe OO. Local knowledge, use pattern and geographical distribution of Moringa oleifera Lam. (Moringaceae) in
Nigeria. J Ethnopharmacol. 2013;150(2):682–91.
Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse
GD, Nhachi CFB. Effect of Moringa oleifera Lam. leaf powder
on the pharmacokinetics of nevirapine in HIV-infected adults: a
one sequence cross-over study. AIDS Res Ther. 2017;14(1):12.
Ogbuagu EN, Ufearo S, Ogbuagu CN, Okonkwo R. CD4 pattern
in HIV positive patients on HAART exposed to Moringa oleifera
leaf powder in south east Nigeria. Int J Infect Dis. 2016;45:267.
60. Zoung–Kanyi Bissek A, Njie Kinge T, Abena Messomo P, Njamnshi A, Bella Assumpta L, Wilfried A, et al. Guide national de
prise en charge des personnes vivant avec le VIH/SIDA – Cameroun. http://apps.who.int/medicinedocs/documents/s16436f/s1643
6f.pdf. Accessed 13 June 2018.
61. Hunt KJ, Coelho HF, Wider B, Perry R, Hung SK, Terry R, et al.
Complementary and alternative medicine use in England: results
from a national survey. Int J Clin Pract. 2010;64(11):1496–502.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
13